Approaches to slowing the progression of COPD

Chronic obstructive pulmonary disease (COPD) is a major health problem across the world and its medical, societal and economic impacts continue to grow. There are several hypotheses regarding the pathogenesis of COPD and important new information on airway inflammation, oxidative stress and proteoly...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Current opinion in pulmonary medicine 2003-03, Vol.9 (2), p.125-130
1. Verfasser: Altose, Murray D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 130
container_issue 2
container_start_page 125
container_title Current opinion in pulmonary medicine
container_volume 9
creator Altose, Murray D
description Chronic obstructive pulmonary disease (COPD) is a major health problem across the world and its medical, societal and economic impacts continue to grow. There are several hypotheses regarding the pathogenesis of COPD and important new information on airway inflammation, oxidative stress and proteolysis in the lungs that are important for the development of effective treatments. The differences in susceptibility to COPD among cigarette smokers and the common familial risk of developing disease point to important genetic influences. The identification of candidate gene loci and various gene polymorphisms have improved our understanding of the mechanisms by which genetic factors predispose for COPD. The beneficial effects of smoking cessation in slowing the decline in lung function and the progression of disease have been clearly established. Whether other factors such as mucus hypersecretion, respiratory infections and airway hyperreactivity contribute to disease progression independent of cigarette smoking is still being debated. There is new interest in dietary strategies to prevent or control COPD and preliminary information suggesting the usefulness of diets favoring antioxidant-rich foods. On the other hand several large, long-term, randomized, controlled clinical trials have failed to show a beneficial effect of either anticholinergics or corticosteroids in slowing the rate of decline in lung function in COPD. Corticosteroid treatment, however, appears to reduce the frequency of COPD exacerbations and there is some suggestion that it may also reduce the risk of death in patients with severe COPD.
doi_str_mv 10.1097/00063198-200303000-00006
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73018611</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73018611</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3566-4f39029bbf169c71c8a40cc79168d43e14223d4ebea8070c17749fa73dd21a773</originalsourceid><addsrcrecordid>eNp1kctOwzAQRS0EoqXwCygrdoEZ27HjZVWeUqWygLXlOE4TSOtiJ6r4e1JaYIVmMaOrOw-dISRBuEZQ8gYABEOVpxSADQGQwk47ImPMGKZCSTweapCQZjSXI3IW4xsAUoV4SkZIM8mFomOSTjeb4I2tXUw6n8TWb5v1Mulqlwz6MrgYG79OfJXMFs-35-SkMm10F4c8Ia_3dy-zx3S-eHiaTeepZZkQKa-YAqqKokKhrESbGw7WSoUiLzlzyCllJXeFM_lwokUpuaqMZGVJ0UjJJuRqP3e44aN3sdOrJlrXtmbtfB-1ZIC5QByM-d5og48xuEpvQrMy4VMj6B0q_YNK_6LS36iG1svDjr5YufKv8cBmMPC9YevbzoX43vZbF3TtTNvV-r8XsC-mr3E8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73018611</pqid></control><display><type>article</type><title>Approaches to slowing the progression of COPD</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Altose, Murray D</creator><creatorcontrib>Altose, Murray D</creatorcontrib><description>Chronic obstructive pulmonary disease (COPD) is a major health problem across the world and its medical, societal and economic impacts continue to grow. There are several hypotheses regarding the pathogenesis of COPD and important new information on airway inflammation, oxidative stress and proteolysis in the lungs that are important for the development of effective treatments. The differences in susceptibility to COPD among cigarette smokers and the common familial risk of developing disease point to important genetic influences. The identification of candidate gene loci and various gene polymorphisms have improved our understanding of the mechanisms by which genetic factors predispose for COPD. The beneficial effects of smoking cessation in slowing the decline in lung function and the progression of disease have been clearly established. Whether other factors such as mucus hypersecretion, respiratory infections and airway hyperreactivity contribute to disease progression independent of cigarette smoking is still being debated. There is new interest in dietary strategies to prevent or control COPD and preliminary information suggesting the usefulness of diets favoring antioxidant-rich foods. On the other hand several large, long-term, randomized, controlled clinical trials have failed to show a beneficial effect of either anticholinergics or corticosteroids in slowing the rate of decline in lung function in COPD. Corticosteroid treatment, however, appears to reduce the frequency of COPD exacerbations and there is some suggestion that it may also reduce the risk of death in patients with severe COPD.</description><identifier>ISSN: 1070-5287</identifier><identifier>EISSN: 1531-6971</identifier><identifier>DOI: 10.1097/00063198-200303000-00006</identifier><identifier>PMID: 12574692</identifier><language>eng</language><publisher>United States: Lippincott Williams &amp; Wilkins, Inc</publisher><subject>Adrenal Cortex Hormones - therapeutic use ; Bronchodilator Agents - therapeutic use ; Cholinesterase Inhibitors - therapeutic use ; Clinical Trials as Topic ; Combined Modality Therapy ; Diet Therapy ; Humans ; Lung - physiopathology ; Pulmonary Disease, Chronic Obstructive - drug therapy ; Pulmonary Disease, Chronic Obstructive - epidemiology ; Pulmonary Disease, Chronic Obstructive - physiopathology ; Respiratory Tract Infections - physiopathology ; Smoking Cessation ; Theophylline - therapeutic use</subject><ispartof>Current opinion in pulmonary medicine, 2003-03, Vol.9 (2), p.125-130</ispartof><rights>2003 Lippincott Williams &amp; Wilkins, Inc.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3566-4f39029bbf169c71c8a40cc79168d43e14223d4ebea8070c17749fa73dd21a773</citedby><cites>FETCH-LOGICAL-c3566-4f39029bbf169c71c8a40cc79168d43e14223d4ebea8070c17749fa73dd21a773</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12574692$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Altose, Murray D</creatorcontrib><title>Approaches to slowing the progression of COPD</title><title>Current opinion in pulmonary medicine</title><addtitle>Curr Opin Pulm Med</addtitle><description>Chronic obstructive pulmonary disease (COPD) is a major health problem across the world and its medical, societal and economic impacts continue to grow. There are several hypotheses regarding the pathogenesis of COPD and important new information on airway inflammation, oxidative stress and proteolysis in the lungs that are important for the development of effective treatments. The differences in susceptibility to COPD among cigarette smokers and the common familial risk of developing disease point to important genetic influences. The identification of candidate gene loci and various gene polymorphisms have improved our understanding of the mechanisms by which genetic factors predispose for COPD. The beneficial effects of smoking cessation in slowing the decline in lung function and the progression of disease have been clearly established. Whether other factors such as mucus hypersecretion, respiratory infections and airway hyperreactivity contribute to disease progression independent of cigarette smoking is still being debated. There is new interest in dietary strategies to prevent or control COPD and preliminary information suggesting the usefulness of diets favoring antioxidant-rich foods. On the other hand several large, long-term, randomized, controlled clinical trials have failed to show a beneficial effect of either anticholinergics or corticosteroids in slowing the rate of decline in lung function in COPD. Corticosteroid treatment, however, appears to reduce the frequency of COPD exacerbations and there is some suggestion that it may also reduce the risk of death in patients with severe COPD.</description><subject>Adrenal Cortex Hormones - therapeutic use</subject><subject>Bronchodilator Agents - therapeutic use</subject><subject>Cholinesterase Inhibitors - therapeutic use</subject><subject>Clinical Trials as Topic</subject><subject>Combined Modality Therapy</subject><subject>Diet Therapy</subject><subject>Humans</subject><subject>Lung - physiopathology</subject><subject>Pulmonary Disease, Chronic Obstructive - drug therapy</subject><subject>Pulmonary Disease, Chronic Obstructive - epidemiology</subject><subject>Pulmonary Disease, Chronic Obstructive - physiopathology</subject><subject>Respiratory Tract Infections - physiopathology</subject><subject>Smoking Cessation</subject><subject>Theophylline - therapeutic use</subject><issn>1070-5287</issn><issn>1531-6971</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctOwzAQRS0EoqXwCygrdoEZ27HjZVWeUqWygLXlOE4TSOtiJ6r4e1JaYIVmMaOrOw-dISRBuEZQ8gYABEOVpxSADQGQwk47ImPMGKZCSTweapCQZjSXI3IW4xsAUoV4SkZIM8mFomOSTjeb4I2tXUw6n8TWb5v1Mulqlwz6MrgYG79OfJXMFs-35-SkMm10F4c8Ia_3dy-zx3S-eHiaTeepZZkQKa-YAqqKokKhrESbGw7WSoUiLzlzyCllJXeFM_lwokUpuaqMZGVJ0UjJJuRqP3e44aN3sdOrJlrXtmbtfB-1ZIC5QByM-d5og48xuEpvQrMy4VMj6B0q_YNK_6LS36iG1svDjr5YufKv8cBmMPC9YevbzoX43vZbF3TtTNvV-r8XsC-mr3E8</recordid><startdate>200303</startdate><enddate>200303</enddate><creator>Altose, Murray D</creator><general>Lippincott Williams &amp; Wilkins, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200303</creationdate><title>Approaches to slowing the progression of COPD</title><author>Altose, Murray D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3566-4f39029bbf169c71c8a40cc79168d43e14223d4ebea8070c17749fa73dd21a773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adrenal Cortex Hormones - therapeutic use</topic><topic>Bronchodilator Agents - therapeutic use</topic><topic>Cholinesterase Inhibitors - therapeutic use</topic><topic>Clinical Trials as Topic</topic><topic>Combined Modality Therapy</topic><topic>Diet Therapy</topic><topic>Humans</topic><topic>Lung - physiopathology</topic><topic>Pulmonary Disease, Chronic Obstructive - drug therapy</topic><topic>Pulmonary Disease, Chronic Obstructive - epidemiology</topic><topic>Pulmonary Disease, Chronic Obstructive - physiopathology</topic><topic>Respiratory Tract Infections - physiopathology</topic><topic>Smoking Cessation</topic><topic>Theophylline - therapeutic use</topic><toplevel>online_resources</toplevel><creatorcontrib>Altose, Murray D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current opinion in pulmonary medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Altose, Murray D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Approaches to slowing the progression of COPD</atitle><jtitle>Current opinion in pulmonary medicine</jtitle><addtitle>Curr Opin Pulm Med</addtitle><date>2003-03</date><risdate>2003</risdate><volume>9</volume><issue>2</issue><spage>125</spage><epage>130</epage><pages>125-130</pages><issn>1070-5287</issn><eissn>1531-6971</eissn><abstract>Chronic obstructive pulmonary disease (COPD) is a major health problem across the world and its medical, societal and economic impacts continue to grow. There are several hypotheses regarding the pathogenesis of COPD and important new information on airway inflammation, oxidative stress and proteolysis in the lungs that are important for the development of effective treatments. The differences in susceptibility to COPD among cigarette smokers and the common familial risk of developing disease point to important genetic influences. The identification of candidate gene loci and various gene polymorphisms have improved our understanding of the mechanisms by which genetic factors predispose for COPD. The beneficial effects of smoking cessation in slowing the decline in lung function and the progression of disease have been clearly established. Whether other factors such as mucus hypersecretion, respiratory infections and airway hyperreactivity contribute to disease progression independent of cigarette smoking is still being debated. There is new interest in dietary strategies to prevent or control COPD and preliminary information suggesting the usefulness of diets favoring antioxidant-rich foods. On the other hand several large, long-term, randomized, controlled clinical trials have failed to show a beneficial effect of either anticholinergics or corticosteroids in slowing the rate of decline in lung function in COPD. Corticosteroid treatment, however, appears to reduce the frequency of COPD exacerbations and there is some suggestion that it may also reduce the risk of death in patients with severe COPD.</abstract><cop>United States</cop><pub>Lippincott Williams &amp; Wilkins, Inc</pub><pmid>12574692</pmid><doi>10.1097/00063198-200303000-00006</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1070-5287
ispartof Current opinion in pulmonary medicine, 2003-03, Vol.9 (2), p.125-130
issn 1070-5287
1531-6971
language eng
recordid cdi_proquest_miscellaneous_73018611
source MEDLINE; Journals@Ovid Complete
subjects Adrenal Cortex Hormones - therapeutic use
Bronchodilator Agents - therapeutic use
Cholinesterase Inhibitors - therapeutic use
Clinical Trials as Topic
Combined Modality Therapy
Diet Therapy
Humans
Lung - physiopathology
Pulmonary Disease, Chronic Obstructive - drug therapy
Pulmonary Disease, Chronic Obstructive - epidemiology
Pulmonary Disease, Chronic Obstructive - physiopathology
Respiratory Tract Infections - physiopathology
Smoking Cessation
Theophylline - therapeutic use
title Approaches to slowing the progression of COPD
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T17%3A03%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Approaches%20to%20slowing%20the%20progression%20of%20COPD&rft.jtitle=Current%20opinion%20in%20pulmonary%20medicine&rft.au=Altose,%20Murray%20D&rft.date=2003-03&rft.volume=9&rft.issue=2&rft.spage=125&rft.epage=130&rft.pages=125-130&rft.issn=1070-5287&rft.eissn=1531-6971&rft_id=info:doi/10.1097/00063198-200303000-00006&rft_dat=%3Cproquest_cross%3E73018611%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73018611&rft_id=info:pmid/12574692&rfr_iscdi=true